Biomaterials 2022 April 20 [Link] Robert C Sabatelle, Rong Liu, Yin P Hung, Eric Bressler, Eliza J Neal, Andrew Martin, Iriny Ekladious, Mark W Grinstaff, Yolonda L Colson Abstract Peritoneal mesothelioma is an aggressive disease with a median survival of under three years, due to a lack of effective treatment options. Mesothelioma is traditionally considered…

Read More

Journal of Thoracic Oncology 2022 April 27 [Link] Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y C Gary Lee, Ian M Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Røe Abstract Introduction: Pleural mesothelioma (PM) is an aggressive…

Read More

Virchows Archiv 2022 April 24 [Link] Francesca Napoli, Ida Rapa, Stefania Izzo, Angelica Rigutto, Roberta Libener, Chiara Riganti, Paolo Bironzo, Riccardo Taulli, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract The standard front-line treatment for pleural mesothelioma (PM) is pemetrexed-based chemotherapy, whose major target is thymidylate synthase (TS). In several cancer models, miR-215 and…

Read More

Cancers 2022 April 16 [Link] Tugce Kutuk, Haley Appel, Maria Carolina Avendano, Federico Albrecht, Paul Kaywin, Suyen Ramos, Melanie E Suarez-Murias, Minesh P Mehta, Rupesh Kotecha Abstract Purpose: The objectives of this study were to evaluate the implementation, device usage rates, clinical outcomes, and treatment-related toxicities associated with TTFields and pemetrexed plus platinum-based chemotherapy in…

Read More

BMC Cancer 2022 April 20 [Link] Barbara Ziółkowska, Bożena Cybulska-Stopa, Dimitrios Papantoniou, Rafał Suwiński Abstract Background: Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the pleural cavity linked to asbestos exposure. The combination of pemetrexed and platinum is a standard first-line therapy for malignant pleural mesothelioma. Despite some progress, almost all MPM patients…

Read More

Lung Cancer 2022 March 29 [Link] Michael Koller, Jammbe Z Musoro, Krzysztof Tomaszewski, Corneel Coens, Madeleine T King, Mirjam A G Sprangers, Mogens Groenvold, Kim Cocks, Galina Velikova, Hans-Henning Flechtner, Andrew Bottomley Abstract Objectives: A minimally important difference (MID) is the smallest difference in quality of life (QoL) perceived as relevant by patients or clinicians.…

Read More

Lung Cancer 2022 March 21 [Link] Arnaud Scherpereel, Scott Antonia, Yolanda Bautista, Francesco Grossi, Dariusz Kowalski, Gérard Zalcman, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Xiaowu Sun, Rachael Lawrance, Xiaoqing Zhang, Melinda J Daumont, Bryan Bennett, Mike McKenna, Paul Baas Abstract Objective: In CheckMate 743 (NCT02899299), nivolumab…

Read More

The Lancet Oncology 2022 April [Link] Hedy L Kindler, Silvia Novello, Alessandra Bearz, Giovanni L Ceresoli, Joachim G J V Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Jennens, Luana Calabrò, Jacobus A Burgers, Armando Santoro, Susana Cedrés, Piotr Serwatowski, Santiago Ponce, Jan P Van Meerbeeck, Anna K Nowak, George Blumenschein Jr, Jonathan…

Read More

European Journal of Cancer 2022 March 28 [Link] Giuseppe Luigi Banna, Alessio Signori, Alessandra Curioni-Fontecedro, Alessio Cortellini, Marta Ponzano, Emilio Francesco Giunta, Sara Elena Rebuzzi, Samuel Chan, Vittorio Gebbia, Ronwyn van Eeden, Alfredo Addeo, Christian Ottensmeier Abstract Background: Randomised controlled trials (RCTs) with systemic therapies for patients with pre-treated mesothelioma have reported equivocal efficacy results…

Read More

Lung Cancer 2022 March 2 [Link] Alexander Davis, Helen Ke, Steven Kao, Nick Pavlakis Abstract The treatment paradigm for malignant pleural mesothelioma (MPM) has changed little in the last 18 years. Radical intent treatment, consisting of surgical resection, radiotherapy and chemotherapy, has been offered to a highly select few; however, there is little randomised evidence…

Read More